Device Trial Radar · NCT00180297
Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead
Last checked: Nov 20, 2026Latest source record: Oct 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
215
Actual
Start
Apr 2005
Primary completion
Sep 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- Collaborators
- Guidant Corporation
- First posted
- Sep 16, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of the implant of a ICD lead of defibrillation in the septum of the right ventricle
Conditions
- Ventricular Tachycardia
- Ventricular Fibrillation
Interventions
Endotak Reliance GDevice
Reliance G is a defibrillation lead to be placed in the right ventricle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Implant Success Rate at Septal SiteTime frame: At implant
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
CH Amiens
Amiens, France
CHU Angers
Angers, France
CH Besancon
Besançon, France
15 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.